Search Results
Results for: ""
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
SAN DIEGO – October 6, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter...
READ MORE →A New Era in Acromegaly Care: Putting Patients at the Center
Isabel KalofonosChief Commercial Officer, Crinetics Pharmaceuticals For years, people living with acromegaly have navigated a care landscape that has remained...
READ MORE →Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Acromegaly in Adults
Crinetics announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY™ (paltusotine) for the first-line treatment of adults with...
READ MORE →FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
Crinetics will host an investor conference call on September 25, at 6:00 pm Eastern Time to discuss the FDA approval...
READ MORE →Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics grants non-qualified stock option awards to purchase an aggregate of 62,475 shares of its common stock and granted an...
READ MORE →Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
Crinetics announced that the U.S. FDA granted Orphan Drug Designation for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor...
READ MORE →Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an...
READ MORE →Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reports second quarter 2025 financial results and provided a business update on August 7, 2025 at 4:30PM ET.
READ MORE →Webcast: Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results
August 7, 2025
READ MORE →Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Crinetics announced new data from its clinical development program evaluating once-daily, oral investigational PALSONIFYTM (paltusotine) in acromegaly at ENDO 2025.
READ MORE →Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
